Who are we?
BioAvenir is a family owned pharmaceutical company specializing in licensing, registering and commercializing pharmaceuticals and special products in Israel both to the private and institutional market. The Company is registered in Israel and initiated its marketing actively during the second half of 2004. The company’s shareholders are engaged in a business activity In the United Kingdom.
To be a qualified agent for foreign pharmaceutical companies in Israel.
To be a cooperation partner for small to medium size companies within the field of pharmaceutical and biotechnology.
Licensing -BioAvenir has formed partnerships with several companies operating in regulated markets, mainly in the EU and North America. These partnerships consist of license and long term supply agreements. With BioAvenir’s ability to register and market products in Israel, and it’s desire to form long term supply partnership, BioAvenir is the ideal partner for medium sized pharmaceutical and biotechnology companies.
Sales and Marketing – BioAvenir aims mainly to an added value generic products for hospitals, “difficult generic” which have an advantage over potential competitors, Medical devices and specialty drugs.
Sales and Marketing – BioAvenir aims mainly to an added value generic for hospitals, difficult generic, biosimilar, pain management drugs, drugs to treat rare diseases / orphan drugs, niche RX specially drugs.
Our Values & Competencies
Excellent business relationship with major institutions- health services providers and hospitals. Regulatory and registration expertise.Dedicated to high quality. Well acquaintance and experience in the field of Ophthalmology. Excellent personal relationship with opinion and policy leaders.
- Excellent personal and business relationship with major institutions- health organizations and hospitals.
- Regulatory and registration expertise.
- Dedication to high quality.
- Excellent personal relationship with KOL’S.
BioAvenir’s shareholders have established a pharmaceutical company in Cyprus, called Nespera Pharma. Nespera is specializing in licensing and commercializing of pharmaceuticals and special products outside of Israel, mainly in North America and Europe. We have also established a company based In the United Kingdom which is dedicated to the development and commercializing of products in the field of pulmonary hypertension and cognitive, muscular and endocrine disorder.
Drugs Disributed by BioAvenir Ltd
Nucleotide Reverse Transcriptase Inhibitor. Aciclovir 250 mg. VIALS (pwdr. for sol. for IV inject): 5 x 10
ml. See lit.
Tmt. herpes simplex infects., severe initial
genital herpes in non-immune comp.
pts., prophylax. herpes simplex infects. in
immune-comp. pts. Tmt. varicella zoster
infects., herpes simplex encephalit.,
herpes simplex infects. in neonate/infant
up to 3 mths old.
Penicillin, β Lactamase Inhibitors. Clavulanic Acid (as potassium clavulanate) 200 mg/vial, Amoxycillin (as sodium) 1,000 mg/vial. VIALS (sol. for inject.): 1, 10, 100X20 ml. I.V. See lit.
Short-term tmt. bact. infects. caused by
suscept. organs. resist. to other betalactamase
Carbonic Anhydrase Inhibitor, β Antagonist. Dorzolamide HCl 20 mg/ml, Timolol Maleate 5 mg/ml. SOL.:5 ML. 1dr ×2/d in the affected eye. See lit.
For the tmt. of elevat. intraoc. press. (IOP) in pts. with ocular hypertens., open-ang. glauc., or other second. open-ang. glauc. when concom. ther. is appropr.
C/I: Hypersens. Pts. with past/present pulmon. dis. e.g.: asthma, severe chron. obstruct. bronchit. Pts. with bradycard., HF, arrhythm. Pts. with renal impair.,renal dis., nephrolithias. Pts. with hyperchlorem. acidosis.
Antifungal. Fluconazole 2 mg/ml. AMP.:1, 10×50, 100, 200 ml. Adult.: Cryptococcal meningitis/cryptococcal infec. at other sites: 400mg on the 1st day follow. by 200 mg - 400 mg once dly. Durat. of tmt. for cryptococcal infec. will depend on the clinic. and mycological response, but is usual. at least 6-8 wks. for cryptococcal meningitis. For the prevent. of relapse of cryptococcal meningitis in pts. with AIDS, after the patient receives a full course of prim. therapy, this sol. may be admin. indefinitely at a dly. dose of 200 mg. Candidaemia, disseminated
candidiasis and other invas. candid. infect.: 400mg on the 1st day follow. by 200mg dly. Depend. on the clinic. response, the dose may be incr. to 400mg dly. Durat. of tmt. is based upon the clinic. response. Mucosal Candidiasis, Oropharyng. candidiasis: 50mg×1/d for 7-14 d. Tmt. can be continued for longer periods in pts. with sever. comprom. immun. func. For atrophic oral candidiasis assoc. with dentures, 50mg×1/d for 14 d. admin. concurr. with local antisep. measures to the denture. Other candidal infec. of mucosa (except vag. candidiasis, e.g. esophagitis, non-invas.
bronchopulmon. infec., candiduria,
mucocutaneous candidiasis etc.: 50mg-100mg dly., given for 14-30 d. Child. A max. dosage of 400 mg dly. should not be exceeded in child. As with similar infec. in adults, the durat. of tmt. is based on the clin. and mycological response, admin. as a single dly. dose. Children>4 four wks. of age: Mucosal Candidiasis: 3 mg/kg dly. Load. ing dose of 6 mg/kg may be used on the 1st day, to achieve steady state levels more rapid. System. Candidiasis, cryptococcal infec., 6-12 mg/kg dly., depend. on the sever. of the dis. Child. <4 wks. of age and younger max dose 12 mg/ kg every 72 hrs. should not be exceeded in child. in the 1st two weeks of life. For child. between 3rd and 4th wk. of life, 12 mg/kg every 48 hrs.
should not be exceeded.
Systemic candidiasis, mucosal candidiasis, cryptococcosis.
C/I: Pts with known hypersens. to fluconazole or to related azole comp. Concom. use with cisapride, zidovudine, rifabutine, tacrolimus. The use of fluconazole in pts. concur. taking astemizole or other drugs metabol. by the cytochr. P450 syst., may be assoc. with elevat.in serum levels of these drugs. In the absence of definitive inform., caution should be used when co admin. fluconazole. Pts. should be